PerkinElmer Adds HPLC Columns to Consumables Portfolio

PerkinElmer Adds HPLC Columns to Consumables Portfolio

March 8, 2021 at 10:00 AM EST

Delivering Full, Performance-Boosting Workflow Solutions for Pharma, Chemical, Food and Environmental Testing Labs

 

WALTHAM, Mass. – March, 8, 2021 PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it has added state-of-the-art columns and chemistries to its LC consumables portfolio by acquiring ES Industries, based in West Berlin, New Jersey in the U.S.

ES Industries is known for its innovative and highly efficient HPLC and supercritical fluid chromatography (SFC) column chemistries. The team has over 40 years of experience delivering columns with superior reliability, scalability, and reproducibility that are used routinely for method development processes, LC/MS analysis, quality control and preparative purification.

Building on PerkinElmer’s recently announced LC 300TM HPLC/UHPLC and SimplicityChromTM CDS solution, along with its world class reagents and OneSource® laboratory services, the addition of these column technologies brings customers, such as those in pharmaceuticals/biopharmaceuticals, chemicals, food safety and environmental industries, the convenience of a single buying channel for their full LC workflow needs, along with better and faster analyses.

Commenting on the new addition to the PerkinElmer LC line-up, Suneet Chadha, VP and GM of Applied Markets, PerkinElmer said, “We know that labs are looking to streamline and simplify their LC analyses and maximize productivity while also meeting ever-increasing quality and regulatory demands. By augmenting our portfolio with HPLC columns technology, expertise and manufacturing capabilities, we can now innovate faster and provide complete end to end workflow solutions. We are excited that these offerings will shorten the time from sample to result for our customers and help deliver enhanced lab performance.”

For more information please visit:

https://www.perkinelmer.com/category/liquid-chromatography-hplc-uhplc-instruments; https://esind.com/

About PerkinElmer

PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) the United Kingdom’s withdrawal from the European Union; (21) our ability to obtain future financing; (22) restrictions in our credit agreements; (23) discontinuation or replacement of LIBOR;  (24) significant fluctuations in our stock price; (25) reduction or elimination of dividends on our common stock; and (26) other factors which we describe under the caption "Risk Factors" in our most recent annual report on Form 10-K and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

 

Media Contact:
Jennifer McNeil
jennifer.mcneil@perkinelmer.com
+1 508.380.2902

Related Links

IR Contact

ir@perkinelmer.com
(781) 663 - 6900
940 Winter Street
Waltham, MA 02451
United States
www.perkinelmer.com

Transfer Agent

Mailing addresses
Correspondence should be mailed to:
Computershare
P.O. Box 505000
Louisville, KY 40233

Overnight correspondence should be sent to:
Computershare
462 South 4th Street, Suite 1600
Louisville, KY 40202

Shareholder website www.computershare.com/investor
Shareholder online inquiries
www-us.computershare.com/investor/Contact